Gland Pharma jumps as USFDA concludes pre-approval inspection at Visakhapatnam facility
Gland Pharma is currently trading at Rs. 1616.15, up by 20.65 points or 1.29% from its previous closing of Rs. 1595.50 on the BSE.
The scrip opened at Rs. 1604.85 and has touched a high and low of Rs. 1649.95 and Rs. 1587.10 respectively. So far 4578 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1412.00 on 12-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1649.95 and Rs. 1473.45 respectively. The current market cap of the company is Rs. 26989.63 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.84% and 8.33% respectively.
United States Food and Drug Administration (USFDA) has concluded Pre-approval inspection (PAI) for Sterile APIs at Gland Pharma’s facility at JNPC, Visakhapatnam. The inspection was conducted from February 19, 2025 to February 25, 2025.
The said inspection was concluded with three form 483 observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the USFDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
